Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy – Drugs In Development, 2023’, provides an overview of the Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy
- The report reviews pipeline therapeutics for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy therapeutics and enlists all their major and minor projects
- The report assesses Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
AB Science SAAcrotech Biopharma LLC
Advenchen Laboratories LLC
Affimed GmbH
Angel Pharmaceuticals Inc
Antengene Corp Ltd
Ascentage Pharma Group International
Astex Pharmaceuticals Inc
AstraZeneca Plc
Autolus Therapeutics Plc
Axter Therapeutics Ltd
Baylor College of Medicine
Beijing Boren Hospital
Biosyngen Pte Ltd
Bristol-Myers Squibb Co
CGeneTech (Suzhou China) Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Corvus Pharmaceuticals Inc
CSPC Pharmaceutical Group Ltd
CTI BioPharma Corp
Curon Biopharmaceutical Ltd
Daiichi Sankyo Co Ltd
Evopoint Bioscience Co Ltd
Fundacio Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Guangzhou Bairui Biomedical Technology Co Ltd
Guangzhou BeBetter Medicine Technology Co Ltd
Hutchison MediPharma Ltd
HUYA Bioscience International LLC
iCell Gene Therapeutics LLC
Innate Pharma SA
Innovent Biologics Inc
iOnctura SA
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Kura Oncology Inc
Kyowa Kirin Co Ltd
March Biosciences
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Nanchang University Affiliated Hospital One
Nanjing Bioheng Biotech Co Ltd
Nanjing Sanhome Pharmaceutical Co Ltd
Newave Pharmaceutical Inc
OncoVerity Inc
Ono Pharmaceutical Co Ltd
PersonGen BioTherapeutics (Suzhou) Co Ltd
Pharming Group NV
Prescient Therapeutics Ltd
Sanofi
SciTech Development LLC
Seagen Inc
Secura Bio Inc
Shanghai First Song Therapeutics Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Haihe Biopharma Co Ltd
Shanghai Jiao Tong University School of Medicine
Shanghai Yingli Pharmaceutical Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
SIRPant Immunotherapeutics Inc
Solasia Pharma KK
Sunho (China) Biopharmaceutical Co Ltd
Systimmune Inc
Tarapeutics Science Inc
Viracta Therapeutics Inc
Vyriad Inc
Wuhan Bio-Raid Biotechnology Co Ltd
Wuxi People’s Hospital
Xijing Hospital
Zhejiang University